Hims & Hers Health (NYSE:HIMS) Insider Soleil Boughton Sells 3,462 Shares of Stock

Hims & Hers Health, Inc. (NYSE:HIMS) insider Soleil Boughton sold 3,462 shares of Hims & Hers Health stock in a transaction that occurred on Wednesday, October 28th. The stock was sold at an average price of $27.60, for a total transaction of $95,551.20. Following the transaction, the insider directly owned 293,886 shares in the company, valued at $8,111,253.60. The trade was a 1.16% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Soleil Boughton also recently made the following trade(s):

• On Wednesday, October 14th, Soleil Boughton sold 3,461 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.06, for a total transaction of $100,576.66.
• On Wednesday, September 30th, Soleil Boughton sold 3,461 shares of Hims & Hers Health stock. The shares were sold at an average price of $29.17, for a total transaction of $100,957.37.
• On Wednesday, September 16th, Soleil Boughton sold 6,236 shares of Hims & Hers Health stock. The shares were sold at an average price of $27.86, for a total value of $173,734.96.
• On Wednesday, September 2nd, Soleil Boughton sold 3,458 shares of Hims & Hers Health stock. The stock was sold at an average price of $28.33, for a total transaction of $97,965.14.
• On Wednesday, August 19th, Soleil Boughton sold 25,111 shares of Hims & Hers Health stock. The stock was sold at an average price of $27.55, for a total value of $691,808.05.

Hims & Hers Health Stock Performance

Shares of HIMS traded up $0.36 during mid-day trading on Thursday, hitting $29.68. 7,405,111 shares of the company’s stock were exchanged, compared to its average volume of 22,401,816. The company has a quick ratio of 0.87, a current ratio of 0.93 and a debt-to-equity ratio of 4.21. Hims & Hers Health, Inc. has a 52 week low of $13.74 and a 52 week high of $48.34. The firm has a market cap of $6.92 billion, a price-to-earnings ratio of -47.11 and a beta of 2.44. The stock’s 50-day simple moving average is $29.15 and its 200-day simple moving average is $27.11.

Hims & Hers Health (NYSE:HIMS) last announced its quarterly earnings results on Monday, August 10th. The company reported ($0.37) EPS for the quarter, missing analysts’ consensus estimates of ($0.05) by ($0.32). Hims & Hers Health had a negative net margin of 5.51% and a negative return on equity of 6.51%. The firm had revenue of $753.21 million for the quarter, compared to analyst estimates of $698.90 million. During the same period in the previous year, the business posted $0.17 earnings per share. The business’s revenue for the quarter was up 38.2% compared to the same quarter last year. On average, equities research analysts expect that Hims & Hers Health, Inc. will post -0.16 EPS for the current year.

Analyst Upgrades and Downgrades

A number of research analysts have issued reports on HIMS shares. Bank of America upped their price objective on Hims & Hers Health from $30.00 to $32.00 and gave the company a “neutral” rating in a research note on Tuesday, August 11th. Barclays decreased their price target on shares of Hims & Hers Health from $39.00 to $35.00 and set an “overweight” rating on the stock in a report on Friday, August 21st. Zacks Research upgraded shares of Hims & Hers Health from a “strong sell” rating to a “hold” rating in a report on Monday, July 13th. TD Cowen upped their target price on Hims & Hers Health from $25.00 to $30.00 and gave the company a “hold” rating in a report on Tuesday, August 11th. Finally, Citigroup decreased their target price on shares of Hims & Hers Health from $35.00 to $33.00 and set a “neutral” rating for the company in a research note on Tuesday, August 11th. Three research analysts have rated the stock with a Buy rating, eleven have assigned a Hold rating and one has given a Sell rating to the company’s stock. According to MarketBeat, the company currently has a consensus rating of “Hold” and a consensus price target of $32.43.

Institutional Investors Weigh In On Hims & Hers Health

A number of hedge funds have recently added to or reduced their stakes in HIMS. MassMutual Private Wealth & Trust FSB increased its position in shares of Hims & Hers Health by 70.0% during the 2nd quarter. MassMutual Private Wealth & Trust FSB now owns 775 shares of the company’s stock valued at $27,000 after purchasing an additional 319 shares during the last quarter. Sigma Planning Corp boosted its stake in Hims & Hers Health by 1.5% in the 1st quarter. Sigma Planning Corp now owns 26,007 shares of the company’s stock worth $540,000 after purchasing an additional 388 shares during the period. Versant Capital Management Inc boosted its holdings in shares of Hims & Hers Health by 801.2% during the 2nd quarter. Versant Capital Management Inc now owns 748 shares of the company’s stock valued at $26,000 after purchasing an additional 665 shares during the last quarter. BIP Wealth LLC grew its holdings in shares of Hims & Hers Health by 6.0% in the first quarter. BIP Wealth LLC now owns 16,278 shares of the company’s stock valued at $338,000 after purchasing an additional 915 shares in the last quarter. Finally, D.A. Davidson & CO. increased its holdings in shares of Hims & Hers Health by 5.4% in the 1st quarter. D.A. Davidson & CO. now owns 19,617 shares of the company’s stock worth $407,000 after buying an additional 1,000 shares during the last quarter. 63.52% of the stock is currently owned by hedge funds and other institutional investors.

Hims & Hers Health News Summary

Here are the key news stories impacting Hims & Hers Health this week:

• Positive Sentiment: The Department of Health and Human Services reportedly used “enforcement discretion” to temporarily allow compounding of six peptides. The development could expand Hims & Hers’ treatment offerings and support demand for its compounded-care business, prompting a recent rally in the stock. Hims & Hers Jumped 6% as RFK Jr.’s HHS Uses Enforcement Discretion to Open Peptide Compounding
• Positive Sentiment: Hims & Hers also moved higher alongside telehealth peers after Teladoc reported better-than-expected revenue and profit. The broader sector strength may have provided additional support, although the report was not specific to Hims & Hers. Teladoc Soars as Revenue and Profit Beat Estimates
• Neutral Sentiment: Multiple law firms are soliciting investors to serve as lead plaintiff in a securities class action, with a November 2, 2026 deadline. The case covers investors who purchased HIMS shares from August 4, 2025, through July 29, 2026. These announcements largely repeat previously reported litigation information rather than represent a new company filing. HIMS November 2 Lead Plaintiff Deadline
• Negative Sentiment: The lawsuit stems from allegations that Hims & Hers shared private customer information with advertising platforms and used deceptive billing practices. Attorneys also cite the FTC’s broader complaint and a prior stock decline. If substantiated, the claims could create legal costs, regulatory exposure and reputational damage. The allegations have not been proven. Hims & Hers Securities Class Action Alert

About Hims & Hers Health

Hims & Hers Health, Inc is a direct-to-consumer health and wellness company that provides telehealth services through the Hims and Hers platforms. The company connects consumers with licensed healthcare providers through online consultations and offers access to prescription and over-the-counter products, as well as educational and wellness resources.

Its services address areas including sexual health, hair loss, skincare, mental health, weight management and primary care. Depending on the condition and eligibility requirements, customers may receive personalized treatment plans and have prescribed medications delivered directly to them.